Dr. Agnieszka  Vay  Md image

Dr. Agnieszka Vay Md

4160 John R St Rm 2125
Detroit MI 48201
313 769-9436
Medical School: University Of California, Davis School Of Medicine - 2000
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #:
NPI: 1568579415
Taxonomy Codes:

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy


Dr. Agnieszka Vay is associated with these group practices

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found


None Found


Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis. - Gynecologic oncology
Therapy related acute myeloid leukemia (t-AML) is a potential late complication of cytotoxic therapy, and it is of particular concern in the treatment of patients with epithelial ovarian carcinoma (EOC) exposed to multiple courses of chemotherapy during the course of their disease. This study examines the incidence, characteristics and clinical outcomes of patients who developed secondary myeloid-type leukemia after a diagnosis of EOC.National Cancer Institute's Surveillance, Epidemiology and End Results database was pooled for diagnosis of secondary myeloid leukemia after an initial diagnosis of EOC. This group of patients was compared to patients with de novo AML, and to EOC patients who did not develop secondary myeloid leukemia. Demographic, cytopathological and survival data were recorded. Cox Proportional Hazards model was used to calculate hazard ratios (HR) for developing secondary leukemia and to determine the statistically significant variables impacting survival. Kaplan-Meier estimates of survival were obtained and comparisons between the groups were performed using log-rank test.One hundred and nine myeloid leukemia cases were identified among 63,359 patients with a prior diagnosis of EOC for an overall incidence of 0.17%. The median latency to development of leukemia was 4 years (range 0-27 years). Median survival from the time of secondary leukemia diagnosis was 3 months and significantly worse than the 6 month median survival in patients with de novo AML (p<0.001). Age at leukemia diagnosis greater than 65 and development of secondary vs. de novo leukemia had a statistically worse prognosis on multivariate analysis (HR of 2.69, 95%CI 2.60-2.78 and 1.81, 95%CI 1.49-2.20 respectively). The development of secondary leukemia was more common with EOC diagnosis made prior to the platinum/taxane era (HR 6.70, 95%CI 3.69-12.18). There was no difference in median survival between EOC patients who developed AML and those who did not.Development of t-AML is a rare but lethal event among EOC patients, and its incidence has decreased significantly since the use of platinum/taxane-based chemotherapy became the standard of care.Copyright © 2011 Elsevier Inc. All rights reserved.

Map & Directions

4160 John R St Rm 2125 Detroit, MI 48201
View Directions In Google Maps

Nearby Doctors

3901 Beaubien St
Detroit, MI 48201
313 455-5839
4201 St Antione Detroit Medical Center
Detroit, MI 48201
734 640-0887
4646 John R St
Detroit, MI 48201
313 761-1000
4201 St. Antoine 6C Uhc/Dmc
Detroit, MI 48201
313 775-5013
4201 St.Antoine Street 6C, Uhc
Detroit, MI 48201
313 775-5009
3901 Beaubien St Ste 3T72
Detroit, MI 48201
313 455-5533
4160 John R St Suite 917
Detroit, MI 48201
313 454-4525
50 E Canfield St
Detroit, MI 48201
313 454-4525
3901 Beaubien St 3Rd Floor Carls Bldg - Dept Of Urology
Detroit, MI 48201
313 455-5588
50 E Canfield St General Medicine Ambulatory Practice
Detroit, MI 48201
313 454-4525